Literature DB >> 7094509

Codeine disposition in smokers and nonsmokers.

J F Rogers, J W Findlay, J H Hull, R F Butz, E C Jones, J A Bustrack, R M Welch.   

Abstract

The bioavailability of codeine and extent of its transformation to morphine were stated in 12 smoking and 11 nonsmoking subjects after single doses 60 mg IM codeine and 60 mg codeine sulfate orally, given 1 wk apart. Codeine and morphine plasma concentrations over the 12-hr period after drug were determined by radioimmunoassay (RIA). No differences were found between smokers and nonsmokers with respect to maximum plasma concentration (Cmax) of codeine, time to attain this concentration (tmax), codeine plasma half-life (t1/2), or areas under plasma concentration-time curves (AUC) for codeine or morphine. There was a faster, but clinically unimportant, mean apparent plasma clearance in smokers (52.8 +/- 2.3 (SEM) ml/min/70 kg) than in nonsmokers (45.0 +/- 2.1 ml/min/70 kg) after intramuscular injection only. Mean oral codeine bioavailability in smokers (54.8 +/- 4.9%) and in nonsmokers (50.2 +/- 2.1%) did not offer. Plasma morphine AUC values were higher after oral doses than after intramuscular injections, suggesting a first-pass O-demethylation of codeine. For six of these subjects plasma morphine AUC values were very low after both routes of administration, suggesting less O-demethylation of codeine in these than in the remaining 17 subjects. The observation of higher morphine AUC values after oral codeine, coupled with clinical reports of greater analgesic potency with intramuscular codeine, does not support the hypothesis that the analgesic properties of this drug are mediated entirely by biotransformation to morphine.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7094509     DOI: 10.1038/clpt.1982.151

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  18 in total

1.  Lack of effect of paracetamol on the pharmacokinetics and metabolism of codeine in man.

Authors:  A Somogyi; F Bochner; Z R Chen
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

Review 2.  Pharmacokinetics of opioids in liver disease.

Authors:  I Tegeder; J Lötsch; G Geisslinger
Journal:  Clin Pharmacokinet       Date:  1999-07       Impact factor: 6.447

3.  Plasma concentrations of codeine and its metabolite, morphine, after single and repeated oral administration.

Authors:  H Quiding; P Anderson; U Bondesson; L O Boréus; P A Hynning
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

Review 4.  Recent developments in the study of the effects of cigarette smoking on clinical pharmacokinetics and clinical pharmacodynamics.

Authors:  L G Miller
Journal:  Clin Pharmacokinet       Date:  1989-08       Impact factor: 6.447

Review 5.  Drug interactions with tobacco smoking. An update.

Authors:  S Zevin; N L Benowitz
Journal:  Clin Pharmacokinet       Date:  1999-06       Impact factor: 6.447

6.  Interindividual and interethnic differences in the demethylation and glucuronidation of codeine.

Authors:  Q Y Yue; J O Svensson; C Alm; F Sjöqvist; J Säwe
Journal:  Br J Clin Pharmacol       Date:  1989-12       Impact factor: 4.335

7.  Codeine O-demethylation co-segregates with polymorphic debrisoquine hydroxylation.

Authors:  Q Y Yue; J O Svensson; C Alm; F Sjöqvist; J Säwe
Journal:  Br J Clin Pharmacol       Date:  1989-12       Impact factor: 4.335

8.  Infants and young children metabolise codeine to morphine. A study after single and repeated rectal administration.

Authors:  H Quiding; G L Olsson; L O Boreus; U Bondesson
Journal:  Br J Clin Pharmacol       Date:  1992-01       Impact factor: 4.335

9.  Impact of environmental and genetic factors on codeine analgesia.

Authors:  J Desmeules; M P Gascon; P Dayer; M Magistris
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

10.  Comparative disposition of codeine and pholcodine in man after single oral doses.

Authors:  J W Findlay; A S Fowle; R F Butz; E C Jones; B C Weatherley; R M Welch; J Posner
Journal:  Br J Clin Pharmacol       Date:  1986-07       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.